Blackstone Inc
MBX

Blackstone Inc’s MBX Biosciences MBX Stock Holding History

Blackstone Inc’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Buy
+5,533
New +$193K ﹤0.01% 450

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Blackstone Inc's MBX Position: Q2 2026 in Review

Blackstone Inc opened a new position in MBX Biosciences (MBX) in Q2 2026: 5,533 shares worth $305K. The stake represents ﹤0.01% of the portfolio and ranks #450 among its holdings.

173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Blackstone Inc held 5,533 shares of MBX Biosciences worth $305K as of Q2 2026.
  • MBX Biosciences was a new Blackstone Inc position in Q2 2026.
  • MBX Biosciences made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #450 holding.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.